Results 71 to 80 of about 39,473 (264)
l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson’s Disease
l-3,4-Dihydroxyphenylalanine (l-DOPA) is the most effective therapeutic agent for Parkinson’s disease (PD). l-DOPA is traditionally believed to be an inert amino acid that exerts actions and effectiveness in PD through its conversion to dopamine.
Yoshio Goshima +4 more
doaj +1 more source
This work reports one‐pot synthesized novel zwitterionic polydopamine‐silica (ZSiPDA) nanofillers for fabricating PES hybrid ultrafiltration membranes with enhanced hydrophilicity, permeability, and antifouling performance. The optimized membrane achieved over 91% humic acid removal and showed strong potential for municipal wastewater treatment.
Roqaya A. Ismail +5 more
wiley +1 more source
Abstract In a clinical setting, exome sequencing (ES) with copy number variant (CNV) analysis is currently the most effective approach for developmental and epileptic encephalopathies (DEE). However, trio‐based ES is often not feasible in adults, its costs remain prohibitive in certain health care settings, and computational tools for CNV calling still
Laura Licchetta +10 more
wiley +1 more source
Inherited metabolic epilepsies–established diseases, new approaches
Abstract Inherited metabolic epilepsies (IMEs) represent the inherited metabolic disorders (IMDs) in which epilepsy is a prevailing component, often determining other neurodevelopmental outcomes associated with the disorder. The different metabolic pathways affected by individual IMEs are the basis of their rarity and heterogeneity.
Itay Tokatly Latzer, Phillip L. Pearl
wiley +1 more source
Ketogenic diet for infantile epileptic spasms
Abstract Approximately half of all cases of Infantile Epileptic Spasms Syndrome (IESS) do not respond to vigabatrin and hormonal therapies. There is no clear consensus as to the second‐line therapy for IESS. Ketogenic diet (KD) has emerged as an effective treatment for certain drug‐resistant epilepsies and in many cases of IESS.
Morris H. Scantlebury +3 more
wiley +1 more source
The use of L-Dopa in hepatic coma has been the subject of numerous reports since 1970. The following represents our experience with a rather heterogenous group of patients treated at the Massachusetts General Hospital over the past 4 years. Thirty-five patients with severe liver disease, a mean age of 53 +/- 3.5 years, including nutritional cirrhosis ...
J E, Fischer +3 more
openaire +3 more sources
Somatic cell reprogramming for Parkinson's disease treatment
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley +1 more source
Mucuna pruriens (MP), or velvet bean, has been used as an alternative medicine in India for over 4500 years, predominantly due to the natural abundance of the non-protein amino acid L-3,4-dihydroxyphenylalanine (L-DOPA).
Connor R. Phillips +3 more
doaj +1 more source
Purpose: The present study assessed the influence of L-DOPA administration on neostriatal dopamine (DA) transporter (DAT) binding in relation to motor and exploratory behaviors in the rat.Methods: Rats received injections of 5 mg/kg L-DOPA, 10 mg/kg L ...
Susanne eNikolaus +7 more
doaj +1 more source
Hypervision Proton Surgery: The Future Direction of Proton Therapy
ABSTRACT Proton beams provide unique physical advantages characterized by a low entrance dose, negligible exit dose, and a sharp Bragg peak, which enable superior sparing of normal tissues and support safe dose escalation for improved tumor control. However, conventional photon‐based fractionation remains widely used in proton therapy, where prolonged ...
Li Li, Shuanghu Yuan
wiley +1 more source

